Repligen (RGEN) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Repligen (RGEN) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 14.6% versus a loss of 24.3%. Over five years, RGEN leads with a -37.4% price change compared with -79.2% for SRPT. Repligen is the larger company by market cap ($10.27 billion vs $1.91 billion), about 5.4 times the size.
On valuation, Sarepta Therapeutics trades at a lower forward P/E (7.5x vs 61.0x for Repligen).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RGEN | SRPT |
|---|---|---|
| Share price | $161.74 | $18.06 |
| Market cap | $10.27B | $1.91B |
| 1-day change | -3.28% | +3.17% |
| YTD return | +2.05% | -18.68% |
| 1-year return | +14.59% | -24.31% |
| 5-year return | -37.35% | -79.21% |
| P/E ratio (TTM) | 221.56 | — |
| Forward P/E | 61.05 | 7.49 |
| EPS (TTM) | $0.73 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $738.26M | — |
| Revenue growth (YoY) | +16.36% | — |
| Net income (latest FY) | $48.89M | — |
| Gross margin | 52.32% | — |
| Operating margin | 7.47% | — |
| Net margin | 6.62% | — |
| 52-week high | $198.87 | $24.68 |
| 52-week low | $100.99 | $14.68 |
| Distance from 52-week high | -18.67% | -26.84% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +20.53% | +20.35% |
| Average volume | 1.17M | 2.98M |
| Shares outstanding | 63.49M | 105.63M |
| Employees | 2,000 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Repligen is about 5.4 times larger than Sarepta Therapeutics by market value ($10.27B vs $1.91B).
- RGEN has outperformed SRPT by 38.9 percentage points over the past year.
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
RGEN vs SRPT FAQ
Which is bigger, Repligen or Sarepta Therapeutics?
Repligen (RGEN) is larger, with a market capitalization of $10.27B compared with $1.91B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, RGEN or SRPT?
RGEN returned +14.59% over the past 12 months, compared with -24.31% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Repligen and Sarepta Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Repligen and Biotechnology: Pharmaceutical Preparations for Sarepta Therapeutics.